Long-term Renal Function Change after Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema – A 2-Year Retrospective Cohort Study

Running title: Renal function change after intravitreal anti-VEGF in DME

Yi-Chung Fang, MD[1], Ivan Pochou Lai, MD[2], Tso-Ting Lai, MD[2], Ta-Ching Chen, MD PhD[2], Chang-Hao Yang, MD PhD[2,3], Tzyy-Chang Ho, MD[2], Chung-May Yang, MD[2,3], Yi-Ting Hsieh, MD PhD[2]

[1]National Taiwan University Hospital, Taipei, Taiwan.

[2]Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

[3]College of Medicine, National Taiwan University, Taipei, Taiwan

Corresponding author: Yi-Ting Hsieh, MD PhD

ORCID: 0000-0003-2258-154X

Department of Ophthalmology, National Taiwan University Hospital

7 Zhongshan S. Rd., Zhongzheng Dist., Taipei, 10002, Taiwan

Tel: 886-2-23123456 ext. 262131

Fax: 886-2-23934420

E-mail: ythyth@ntuh.gov.tw

Prior Presentation: This manuscript is based on work that has been previously presented in APVRS 2021 virtually on Dec 11–12, 2021. Reference: https://2021.apvrs.org/wp-content/uploads/2021/12/APVRS-Abstract-Book-2021.pdf

Supplementary Table 1. Best-corrected visual acuity, central foveal thickness and optical coherence tomography characteristics at baseline optical coherence tomography in different groups of estimated glomerular filtration rate.

	Baseline eGFR (mL/min)					*P* value
	>120 (n=10)	91-120 (n=14)	61-90 (n=32)	31-60 (n=40)	16-30 (n=12)	
BCVA	0.61±0.36	0.68±0.40	0.68±0.40	0.72±0.34	0.67±0.32	0.85
CFT	462.6±143.0	391.2±134.0	420.8±135.0	456.7±161.6	405.1±78.2	0.52
IRC	10 (100%)	11 (79%)	30 (94%)	39 (98%)	12 (100%)	0.13
SRF	4 (40%)	4 (29%)	4 (13%)	9 (23%)	1(8%)	0.26
EZD	2 (20%)	3 (21%)	7 (22%)	9 (23%)	3 (25%)	1.0

BCVA: best-corrected visual acuity, CFT: central foveal thickness, IRC: intraretinal cysts, SRF: subretinal fluid, EZD: ellipsoid zone disruption.

Supplementary Table 2.Changes of serum HbA1c, systolic blood pressure and serum creatinine at 3, 6, 12, 18 and 24 months after intravitreal injection of anti-vascular endothelial growth factor.

	Serum HbA1c (%)	*P* value	Systolic blood pressure (mm Hg)	*P* value	Serum creatinine (mg/DL)	*P* value
Baseline	7.2 ± 1.2	-	134.0 ± 15.6	-	1.20 ± 0.59	-
Month 3	7.2 ± 1.2	0.39	134.0 ± 14.4	1	1.40 ± 1.04	0.029
Month 6	7.2 ± 1.2	0.54	132.9 ± 14.2	0.48	1.46 ± 1.03	0.002
Month 12	7.1 ± 1.2	0.40	133.9 ± 18.0	0.96	1.51 ± 1.22	< 0.001
Month 18	7.2 ± 1.4	0.89	131.8 ± 15.7	0.26	1.55 ± 1.27	< 0.001
Month 24	7.1 ± 1.2	0.15	132.3 ± 12.3	0.62	1.63 ± 1.45	< 0.001